PMID- 35102114
OWN - NLM
STAT- MEDLINE
DCOM- 20220603
LR  - 20230916
IS  - 1473-5687 (Electronic)
IS  - 0954-691X (Linking)
VI  - 34
IP  - 7
DP  - 2022 Jul 1
TI  - Impact of psoas muscle index assessed by a simple measurement method on 
      tolerability and duration of continued treatment with sorafenib in hepatocellular 
      carcinoma patients.
PG  - 774-781
LID - 10.1097/MEG.0000000000002346 [doi]
AB  - BACKGROUND: In this study, we investigated the impact of simple measurement of 
      psoas muscle index (PMI) on the tolerability of sorafenib treatment of switch 
      from sorafenib to regorafenib. METHOD: This retrospective study enrolled 109 
      patients with Child-Pugh A hepatocellular carcinoma (HCC) treated with sorafenib. 
      Pretreatment PMI was calculated by measuring and multiplying the greatest 
      anterior/posterior and transverse diameters of the psoas muscles on axial 
      computed tomography images at the L3 vertebral level, and normalizing the sum of 
      bilateral psoas muscle areas by the square of the height in meters. We, then, 
      statistically analyzed the association between PMI and adverse events (AEs) to 
      treatment, tolerability of sorafenib, time to treatment failure (TTF), and 
      prognosis in patients stratified according to PMI. RESULT: Patients were divided 
      into high PMI (n = 41) and low PMI (n = 68) groups based on the cutoff PMI values 
      (men: 7.04 cm2/m2; women: 4.40 cm2/m2) determined by receiver operating 
      characteristic curve analysis to determine sorafenib tolerability. Frequencies of 
      all types of severe AEs were higher in the low PMI group (50.0%) than in the high 
      PMI group (29.3%; P = 0.045). The high PMI group (51.2%) had greater tolerance to 
      sorafenib than the low PMI group (25.0%; P = 0.007). Moreover, in multivariable 
      analysis, PMI was associated with sorafenib tolerability (odds ratio 0.26; P = 
      0.008) and was a prognostic factor affecting TTF (hazard ratio 1.77; P = 0.021). 
      CONCLUSION: PMI might be a predictive marker of tolerance to treatment and TTF in 
      HCC patients receiving sorafenib treatment.
CI  - Copyright (c) 2022 Wolters Kluwer Health, Inc. All rights reserved.
FAU - Ogushi, Katsuaki
AU  - Ogushi K
AD  - Gastroenterological Center, Yokohama City University Medical Center, Yokohama.
FAU - Chuma, Makoto
AU  - Chuma M
AD  - Gastroenterological Center, Yokohama City University Medical Center, Yokohama.
FAU - Numata, Kazushi
AU  - Numata K
AD  - Gastroenterological Center, Yokohama City University Medical Center, Yokohama.
FAU - Nozaki, Akito
AU  - Nozaki A
AD  - Gastroenterological Center, Yokohama City University Medical Center, Yokohama.
FAU - Moriya, Satoshi
AU  - Moriya S
AD  - Gastroenterological Center, Yokohama City University Medical Center, Yokohama.
FAU - Uojima, Haruki
AU  - Uojima H
AD  - Department of Gastroenterology, Internal Medicine, Kitasato University School of 
      Medicine, Sagamihara.
FAU - Kondo, Masaki
AU  - Kondo M
AD  - Gastroenterological Center, Yokohama City University Medical Center, Yokohama.
AD  - Department of Gastroenterology, Yokohama City University Hospital, Yokohama.
FAU - Morimoto, Manabu
AU  - Morimoto M
AD  - Department of Gastroenterology, Hepatobiliary and Pancreatic Medical Oncology, 
      Kanagawa Cancer Center Hospital, Yokohama, Japan.
FAU - Maeda, Shin
AU  - Maeda S
AD  - Department of Gastroenterology, Yokohama City University Hospital, Yokohama.
LA  - eng
PT  - Journal Article
DEP - 20220131
PL  - England
TA  - Eur J Gastroenterol Hepatol
JT  - European journal of gastroenterology & hepatology
JID - 9000874
RN  - 9ZOQ3TZI87 (Sorafenib)
SB  - IM
MH  - *Carcinoma, Hepatocellular/diagnostic imaging/drug therapy/pathology
MH  - Female
MH  - Humans
MH  - *Liver Neoplasms/diagnostic imaging/drug therapy/pathology
MH  - Male
MH  - Psoas Muscles/diagnostic imaging/pathology
MH  - Retrospective Studies
MH  - Sorafenib/adverse effects
EDAT- 2022/02/02 06:00
MHDA- 2022/06/07 06:00
CRDT- 2022/02/01 06:07
PHST- 2022/02/02 06:00 [pubmed]
PHST- 2022/06/07 06:00 [medline]
PHST- 2022/02/01 06:07 [entrez]
AID - 00042737-202207000-00008 [pii]
AID - 10.1097/MEG.0000000000002346 [doi]
PST - ppublish
SO  - Eur J Gastroenterol Hepatol. 2022 Jul 1;34(7):774-781. doi: 
      10.1097/MEG.0000000000002346. Epub 2022 Jan 31.